Thank you, Rich, and good morning everyone. In the first quarter, we recorded net sales from our proprietary product portfolio of 244,500,000 slightly above the expectations that we outlined in February, reflecting 5% year over year growth, primarily driven by LYBOLVI. Starting with VIVITROL, net sales in the first quarter were $101,000,000 VIVITROL performance continues to be largely driven by the alcohol dependence indication, which is the primary focus of our promotional efforts and currently accounts for approximately 75% of VIVITROL volume. Looking ahead, we continue to expect VIVITROL net sales for 2025 in the range of $440,000,000 to $460,000,000 For the ARISTADA product family, in the first quarter, net sales were $73,500,000 In 2025, we continue to expect ARISTADA net sales in the range of $335,000,000 to $355,000,000 Turning to LIVALVI, net sales grew 23% year over year to $70,000,000 primarily driven by underlying TRx growth of 22%, with growth coming from both the schizophrenia and bipolar one disorder indications. As we indicated on our last earnings call, gross to net adjustments were approximately 31% in the first quarter, and we expect will remain consistent in the low to mid 30% range for the remainder of 2025.